SpaceX shares under pressure ahead of first earnings report since IPO

InstantWhy

The numbers

CNBC reports SpaceX is set to release its first earnings report as a public company, with the stock trading well below its recent highs. The timing comes two weeks after Tesla's quarterly results disappointed investors. SpaceX has not commented on the upcoming report or its stock performance.

Why it matters

Investors will be looking for revenue guidance and commentary on launch cadence and Starlink subscriber growth to justify the valuation that made it one of the largest IPOs of the year. The pressure is higher because Musk's other public company just delivered results that Wall Street rejected, raising questions about execution across his portfolio.

How this compares

SpaceX shares fell below their IPO price in late July, leaving early public investors with losses, and the stock has dropped roughly half from its post-IPO peak as the broader space sector has been revalued lower. The declines mirror a wider reassessment of growth companies that came public at elevated valuations. Oracle reported earnings on July 28, with investors focused on cloud infrastructure growth and AI spending trends across enterprise software.

What to watch

The report will show whether SpaceX's launch revenue and Starlink subscription business are growing fast enough to support the public valuation. Management commentary on capital spending for the Starship program and any updated guidance will set expectations for the rest of the year. The stock reaction will signal whether investors see the selloff as overdone or justified by the fundamentals.

InstantWhy

Shein offers existing investors $1.1 billion ahead of Hong Kong listing

The fast-fashion retailer is proposing a cash-and-equity package to late-stage backers as it prepares to go pu

SHEIN 2026-08-03 13:04

InstantWhy

Circle Internet shares fall after Morgan Stanley downgrade, TD Cowen starts coverage at Buy

The stablecoin issuer's stock dropped following conflicting analyst calls, with one firm cutting its rating wh

Circle Internet MS 2026-08-03 12:51

InstantWhy

AstraZeneca leads pharma revenue growth as Bristol Myers lags, complicating merger logic

The British drugmaker's stronger growth trajectory contrasts with its American counterpart's performance, addi

AstraZeneca Bristol Myers Squibb 2026-08-03 12:22